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eply
r. Handelsman raises concerns with regard to the interpretation
f findings in the recently published study by Caminiti et al. (1)
nd our accompanying editorial (2). His major point is related to
estosterone’s failure to improve cardiac function while having
eneficial peripheral effects—a dichotomy he suggests may be
xplained by the mood-elevating effects of testosterone. He also
aises concerns with regard to the suboptimal use of saline as
lacebo.
We have no problems with agreeing with Dr. Handelsman’s
iew, and these aspects should be taken into account in the
nterpretation of the effects of testosterone in heart failure. In fact,
he interaction between hormones such as testosterone, neuro-
ransmitters, and inflammatory markers such as cytokines is an
ttractive target for therapy in several disorders such as chronic
eart failure. Thus, if this mechanism contributes to the results of
he study by Caminiti et al. (1), it should encourage rather than
dvise against further studies in this field. Moreover, although the
uthors did not find any effect on myocardial function, further
ong-term studies are needed before making any firm conclusions.
here is clearly a need for new treatment modalities in heart
ailure, and testosterone supplementation might be an interesting
pproach, most probably operating through several mechanisms
ncluding those suggested by Dr. Handelsman.
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2009;54:928–9. pilated Cardiomyopathy
omplicates Pregnancy Outcome:
ut How?
n a recent issue of the Journal, Grewal et al. (1) showed that the
isk of adverse maternal events in pregnant women with dilated
ardiomyopathy (DCM) is considerable, but the underlying mech-
nisms (in addition to increased hemodynamic load) remain
ncertain. Medication was discontinued in many of the women
efore pregnancy or during the first trimester. Even without the
hysical burden of pregnancy, withdrawal of heart failure medica-
ion per se may lead to dramatic hemodynamic deterioration. It
hus would be interesting to know whether the pregnant women
hose medication was discontinued fared worse than those who
ontinued to take their normal medication. It should be noted that
everal beta-blockers, notably labetalol, can be used safely during
regnancy. Thus, pregnancy outcome may not be quite as dismal as
eported by Grewal et al. (1) when adequate therapy is provided.
Four of the 9 cases of heart failure occurred after delivery (1).
xidative stress rises during normal pregnancy, culminating in the
ast trimester. Several signaling pathways have been shown to be
ecessary for protecting the maternal heart, including STAT3. In
mouse model, a deletion of STAT3 caused proteolytic cleavage of
rolactin into a potent antiangiogenic, proapoptotic, and proin-
ammatory factor associated with the development of peripartum
ardiomyopathy (2). It is conceivable that peripartum oxidative
tress caused additional damage to the left ventricle. In this respect,
he fact that 5 women had doxorubicin-induced DCM may be
elevant, because oxidative stress is deemed to play an important
ole in this type of DCM. It thus would be interesting to know
hether Grewal et al. (1) found a difference in pregnancy outcome
etween the women with doxorubicin-induced DCM versus idio-
athic DCM.
Maarten P. van den Berg, MD, PhD
arin Y. van Spaendonck-Zwarts, MD
irk J. van Veldhuisen, MD, PhD
Department of Cardiology
niversity Medical Center Groningen
niversity of Groningen
.O. Box 30.001
700 RB Groningen
he Netherlands
-mail: m.p.van.den.berg@thorax.umcg.nl
doi:10.1016/j.jacc.2010.01.038
EFERENCES
. Grewal J, Siu SC, Ross HJ, et al. Pregnancy outcomes in women with
dilated cardiomyopathy. J Am Coll Cardiol 2010;55:45–52.
. Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin
D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyop-
athy. Cell 2007;128:589–600.
eply
e thank Dr. van den Berg and colleagues for their interest in our
aper (1), and agree that in addition to the increased hemodynamic
